CSIMarket
 
Eliem Therapeutics Inc   (ELYM)
Other Ticker:  
 
 
Price: $2.6400 $0.01 0.380%
Day's High: $2.78 Week Perf: 1.09 %
Day's Low: $ 2.64 30 Day Perf: -8.33 %
Volume (M): 2 52 Wk High: $ 4.25
Volume (M$): $ 6 52 Wk Avg: $2.84
Open: $2.77 52 Wk Low: $2.34



 Market Capitalization (Millions $) 71
 Shares Outstanding (Millions) 27
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -39
 Cash Flow (TTM) (Millions $) 21
 Capital Exp. (TTM) (Millions $) 0

Eliem Therapeutics Inc
Eliem Therapeutics Inc is a pharmaceutical company that focuses on developing innovative therapies for neurological and mental health disorders. The company is committed to discovering and delivering breakthrough treatments that can improve patient outcomes and quality of life. They utilize cutting-edge research and technology to develop novel therapeutics that address unmet medical needs in the field of neuroscience. Eliem Therapeutics Inc aims to make a significant impact on the lives of individuals suffering from these disorders.


   Company Address: PMB #117 Wilmington 98053 DE
   Company Phone Number: 354-3689   Stock Exchange / Ticker: NASDAQ ELYM
   ELYM is expected to report next financial results on March 05, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Eliem Therapeutics Inc

Eliem Therapeutics Inc Surprises Investors with Significant Productivity Growth Despite Operating Deficit

Investors Anticipate Improved Performance for Eliem Therapeutics Inc Despite Operating Deficit
Investors in Eliem Therapeutics Inc were not expecting any changes during the earnings season for the period of July to September 30, 2023; however, the company surprised them with an operating deficit of $-5.001 million for the same period. Although this may seem concerning, it is important to note that the company has demonstrated significant improvement in productivity compared to the third quarter of 2022, particularly in the development sector.
ELYM, as it is commonly referred to, is still in the process of developing its business model. Nevertheless, it has shown potential in reducing the deficit, as it could potentially narrow it down to $-3.968 million for the July to September 30, 2023 period, compared to $-9.682 million in the third quarter of 2022. This indicates that the company is taking steps towards improving its financial performance.

Eliem Therapeutics Inc

Eliem Therapeutics Inc Surges, Reporting Impressive Q2 Results and Steady Growth in Operating Deficit Restoration!

After the large pharmaceutical companies in the Major Pharmaceutical Preparations sector, such as Pfizer and Moderna, have reported their earnings, it is now the turn of smaller entities like Eliem Therapeutics Inc to unveil their financial results. Eliem Therapeutics Inc recently announced that it had booked an operating deficit of $-6.714 million for the second quarter of 2023. However, this figure is actually an improvement from the previous year, as the operating deficit in the second quarter of 2022 was $-13.701 million.
This positive comparison suggests that Eliem Therapeutics Inc is making progress in terms of its financial performance. As emerging businesses like Eliem continue to develop their business strategies, it becomes crucial for them to operate economically in order to reach the next stage of growth. This improvement in operating deficit is certainly a step in the right direction for the company.

Eliem Therapeutics Inc

ELYM Reports Strong Earnings in First Quarter of 2023, Cementing Its Success in the Major Pharmaceutical Preparations Sector

Eliem Therapeutics Inc is a growing pharmaceutical company that specializes in the development of major pharmaceutical preparations. The company has been making significant strides in the pharmaceutical industry, focusing on research and development, manufacturing, and distribution of specialty drugs.
As with most companies operating in the pharmaceutical industry, Eliem Therapeutics Inc is subject to various market fluctuations and regulatory factors. While the company has experienced significant growth over the years, their recent financial reports have left stockholders questioning the company's current trajectory.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com